A case report that suggested that aspirin's effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism

Journal of Clinical Psychopharmacology

Volumn 33, Issue 6, 2013, Pages 812-814

  Riesselman, Amber ^a   Strobl, Bryan ^b   Cooley, Andrew T ^c   De Leon, Jose ^d  

^a Sullivan University   (United States)

^b Central State Hospital   (United States)

^c Kentucky Correctional Psychiatric Center   (United States)

^d EASTERN STATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARIPIPRAZOLE; CLOZAPINE; CYTOCHROME P450 3A4; MULTIDRUG RESISTANCE PROTEIN; OLANZAPINE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; BEDTIME DOSAGE; CLINICAL STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG METABOLISM; DRUG MONITORING; FATTY ACID OXIDATION; GENE EXPRESSION; GENOTYPE; GLUCURONIDATION; HOSPITAL ADMISSION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; TREATMENT RESPONSE;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; ASPIRIN; BIPOLAR DISORDER; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; MALE; VALPROIC ACID;

EID: 84888137126     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182a4ea8f     Document Type: Letter

References (15)

1. DeVane CL. Pharmacokinetics, drug interactions and tolerability of valproate. Psychopharmacol Bull. 2003;37(Suppl 2):25-42.
2. McLaughlin DB, Andrews JA, Hooper WD, et al. Apparent autoinduction of valproate beta-oxidation in humans. Br J Clin Pharmacol. 2000;49:409-415.
3. Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35:1032-1041.
4. Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45:89-93.
5. Bergemann N, Kress KR, Abu-Tair F, et al. Valproate lowers plasma concentration of olanzapine. J Clin Psychopharmacol. 2006;26:432-434.
6. Spina E, D'Arrigo C, Santoro V, et al. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther Drug Monit. 2009;31:758-763.
7. Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008;41:81-91.
8. de Leon J, Santoro V, D'Arrigo C, et al. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012;8:2-24.
9. Sandson NB, Marcucci C, Bourke DL, et al. An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-drug interactions. Am J Psychiatry. 2006;163:1891-1896.
10. de Leon J, Kiesel JL, Fleming M, et al. Valproic acid toxicity associated with low dose of aspirin and low total valproic acid levels: a case report (letter). J Clin Psychopharmacol. 2009;29: 509-511.
11. Sabaawi M, Singh NN, de Leon J. Guidelines for the use of clozapine in individuals with developmental disabilities. Res Dev Disabil. 2006;27:309-336.
12. Diaz FJ, Rivera TE, Josiassen RC, et al. Individualizing drug dosage by using a random intercept linear model. Stat Med. 2007;26:2052-2073.
13. Simpson GM, Josiassen RC, Stanilla JK, et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry. 1999;156: 1744-1750.
14. de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1059-1063.
15. Bender S, Eap CB. Very high cytochrome P4501A2 activity and non-response to clozapine (letter). Arch Gen Psychiatry. 1998;35:1048-1050.